Targeting Lung Cancer Stem Cells: Research and Clinical Impacts.

Related Articles

Targeting Lung Cancer Stem Cells: Research and Clinical Impacts.

Front Oncol. 2017;7:80

Authors: Zakaria N, Satar NA, Abu Halim NH, Ngalim SH, Yusoff NM, Lin J, Yahaya BH

Abstract
Lung cancer is the most common cancer worldwide, accounting for 1.8 million new cases and 1.6 million deaths in 2012. Non-small cell lung cancer (NSCLC), which is one of two types of lung cancer, accounts for 85-90% of all lung cancers. Despite advances in therapy, lung cancer still remains a leading cause of death. Cancer relapse and dissemination after treatment indicates the existence of a niche of cancer cells that are not fully eradicated by current therapies. These chemoresistant populations of cancer cells are called cancer stem cells (CSCs) because they possess the self-renewal and differentiation capabilities similar to those of normal stem cells. Targeting the niche of CSCs in combination with chemotherapy might provide a promising strategy to eradicate these cells. Thus, understanding the characteristics of CSCs has become a focus of studies of NSCLC therapies.

PMID: 28529925 [PubMed - in process]

http://ift.tt/2rcTBHV